The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection

References

• Injection (Medicine)-WIKIPEDIA, The Free Encyclopedia. [webpage on the Internet] Available from: http://en.wikipedia.org/wiki/Injection_(medicine). [updated 2015 March 5]Accessed March 29, 2015
   Google Scholar
• Pharmaceutical drug use principle issuedNational Health and Family Planning Commission of China12112013 Available from: http://news.xinhuanet.com/english/china/2013-12/11/c_132959145.htmAccessed June 29, 2015
   Google Scholar
• PlumbBBrightPGompelsMMUnsworthDJCorrect recognition and management of anaphylaxis: not much change over a decadePostgrad Med J2015913725573132
   PubMed Web of Science ®Google Scholar
• GabrielJIntravenous versus subcutaneous access for palliative care patientsBr J Nurs201423S20S2224464054
   PubMedGoogle Scholar
• StonerKLHarderHFallowfieldLJJenkinsVAIntravenous versus subcutaneous drug administration. which do patients prefer? a systematic reviewPatient Epub2014712
   Google Scholar
• ReggiaRFranceschiniFTincaniACavazzanaISwitching from intravenous to subcutaneous formulation of abatacept: a single-center Italian experience on efficacy and safetyJ Rheumatol20154219319525512476
   PubMed Web of Science ®Google Scholar
• DychterSSGoldDAHallerMFSubcutaneous drug delivery: a route to increased safety, patient satisfaction, and reduced costsJ Infus Nurs20123515416022498485
   PubMedGoogle Scholar
• Herceptin. [webpage on the Internet] Available from: http://www.rxlist.com/herceptin-drug/indications-dosage.htm. [updated 2013 May 12]Accessed March 29, 2015
   Google Scholar
• SanfordMSubcutaneous trastuzumab: a review of its use in HER2-positive breast cancerTarget Oncol20149859424664187
   PubMed Web of Science ®Google Scholar
• PivotXGligorovJMüllerVPrefHer Study GroupPatients’ preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer studyAnn Oncol2014251979198725070545
   PubMed Web of Science ®Google Scholar
• PivotXGligorovJMüllerVPrefHer Study GroupPreference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised studyLancet Oncol20131496297023965225
   PubMed Web of Science ®Google Scholar
• JackischCKimSBSemiglazovVSubcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH studyAnn Oncol20152632032525403587
   PubMed Web of Science ®Google Scholar
• RITUXAN. [webpage on the Internet] Available from: http://www.rxlist.com/rituxan-drug/indications-dosage.htm. [updated 2013 October 21]Accessed March 29, 2015
   Google Scholar
• SalarAAviviIBittnerBComparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB studyJ Clin Oncol2014321782179124821885
   PubMed Web of Science ®Google Scholar
• RuleSCollinsGPSamantaKSubcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United KingdomJ Med Econ20141745946824720836
   PubMedGoogle Scholar
• KaganLTurnerMRBalu-IyerSVMagerDESubcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in ratsPharm Res20122949049921887597
   PubMed Web of Science ®Google Scholar
• DoyleMKRahmanMUFrederickBEffects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trialRheumatology (Oxford)2013521214121923418046
   PubMed Web of Science ®Google Scholar
• SylwestrzakGLiuJStephensonJJRuggieriAPDeVriesAConsidering patient preferences when selecting anti-tumor necrosis factor therapeutic optionsAm Health Drug Benefits20147718124991392
   PubMedGoogle Scholar
• ScarpatoSAntivalleMFavalliEGRIVIERA co-authorsPatient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)Rheumatology (Oxford)20104928929419920093
   PubMed Web of Science ®Google Scholar
• MoreauPPylypenkoHGrosickiSSubcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority studyLancet Oncol20111243144021507715
   PubMed Web of Science ®Google Scholar
• MoreauPKaramaneshtIIDomnikovaNPharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myelomaClin Pharmacokinet20125182382923018466
   PubMed Web of Science ®Google Scholar
• ArnulfBPylypenkoHGrosickiSUpdated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myelomaHaematologica2012971925192822689676
   PubMed Web of Science ®Google Scholar
• BarbeeMSHarveyRDLonialSSubcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferencesAnn Pharmacother2013471136114224259728
   PubMed Web of Science ®Google Scholar
• KamimuraTMiyamotoTYokotaNAokiTItoYAkashiKHigh incidence and severity of injection site reactions in the first cycle compared with subsequent cycles of subcutaneous bortezomibInt J Hematol20139869470124249047
   PubMed Web of Science ®Google Scholar
• MoreauPPylypenkoHGrosickiSSubcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 studyHaematologica20151005e207e21025596270
   PubMed Web of Science ®Google Scholar
• Ethyol. [webpage on the Internet] Available from: http://www.rxlist.com/ethyol-drug.htm. [updated 2008 August 18]Accessed March 29, 2015
   Google Scholar
• BardetEMartinLCalaisGSubcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC 2000–2002 phase III randomized trialJ Clin Oncol20112912713321115863
   PubMed Web of Science ®Google Scholar
• KoukourakisMISimopoulosCMinopoulosGAmifostine before chemotherapy: improved tolerance profile of the subcutaneous over the intravenous routeClin Cancer Res200393288329312960114
   PubMed Web of Science ®Google Scholar
• BardetEMartinLCalaisGPreliminary data of the GORTEC 2000–2002 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapySemin Oncol2002296 suppl 19576012577246
   PubMed Web of Science ®Google Scholar
• RosenfeldCSSuleckiMEvansCShadduckRKComparison of intravenous versus subcutaneous recombinant human granulocyte-macrophage colony-stimulating factor in patients with primary myelo-dysplasiaExp Hematol1991192732772055292
   PubMed Web of Science ®Google Scholar
• LieschkeGJMaherDO’ConnorMPhase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administrationCancer Res1990506066142404573
   PubMed Web of Science ®Google Scholar
• PaulMRamRKuglerESubcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trialAm J Hematol20148924324824178750
   PubMed Web of Science ®Google Scholar
• EguchiKShinkaiTSasakiYSubcutaneous administration of recombinant human granulocyte colony-stimulating factor (KRN8601) in intensive chemotherapy for patients with advanced lung cancerJpn J Cancer Res199081116811741702415
   PubMedGoogle Scholar
• Interleukin 2. [webpage on the Internet] Available from: http://en.wikipedia.org/wiki/Interleukin_2. [updated 2015 January 26]Accessed March 29, 2015
   Google Scholar
• GeertsenPFGoreMENegrierSTouraniJMvon der MaaseHSafety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinomaBr J Cancer2004901156116215026795
   PubMed Web of Science ®Google Scholar
• López-JiménezJPérez-OteyzaJMunozASubcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: results of a prospective, non-randomized studyBone Marrow Transplant1997194294349052907
   PubMed Web of Science ®Google Scholar
• GerthWCBetschelSDZbrozekASImplications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immu-nodeficiencies in CanadaAllergy Asthma Clin Immunol2014102324872821
   PubMed Web of Science ®Google Scholar
• MartinALavoieLGoetghebeurMSchellenbergREconomic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiencyTransfus Med201323556023167310
   PubMed Web of Science ®Google Scholar
• AbolhassaniHSadaghianiMSAghamohammadiAOchsHDRezaeiNHome-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysisJ Clin Immunol2012321180119222730009
   PubMed Web of Science ®Google Scholar
• DucruetTLevasseurMCDes RochesAKafalADicaireRHaddadEPharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric centerJ Allergy Clin Immunol2013131e1e323040368
   PubMed Web of Science ®Google Scholar
• KittnerJMGrimbacherBWulffWJägerBSchmidtREPatients’ attitude to subcutaneous immunoglobulin substitution as home therapyJ Clin Immunol20062640040516783533
   PubMed Web of Science ®Google Scholar
• GardulfABjörvellHAndersenVLifelong treatment with gammaglobulin for primary antibody deficiencies: the patients’ experiences of subcutaneous self-infusions and home therapyJ Adv Nurs1995219179277541407
   PubMed Web of Science ®Google Scholar
• WassermanRLMelamedISteinMRIGSC, 10% with rHuPH20 Study GroupRecombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiencyJ Allergy Clin Immunol2012130951.e957.e22846381
   PubMed Web of Science ®Google Scholar
• BodurHASaygiliFSaygiliSDoganayLHYesilSContinuous infusion of subcutaneous compared to intravenous insulin for tight glycaemic control in medical intensive care unit patientsAnaesth Intensive Care20083652052718714620
   PubMed Web of Science ®Google Scholar
• NeffKDoneganDMacMahonJManagement of parenteral nutrition associated hyperglycaemia: a comparison of subcutaneous and intravenous insulin regimenIr Med J201410714114324908857
   PubMedGoogle Scholar
• FurnaryAPZerrKJGrunkemeierGLStarrAContinuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical proceduresAnn Thorac Surg19996735236010197653
   PubMed Web of Science ®Google Scholar
• PezzarossaATaddeiFCimicchiMCPerioperative management of diabetic subjects. Subcutaneous versus intravenous insulin administration during glucose-potassium infusionDiabetes Care19881152583276477
   PubMed Web of Science ®Google Scholar
• WaznyLDRaymondCBSoodAREngAVerrelliMCost analysis of an intravenous to subcutaneous epoetin α conversionAm J Nephrol20133849650024334854
   PubMed Web of Science ®Google Scholar
• BesarabAReyesCMHornbergerJMeta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patientsAm J Kidney Dis20024043944612200793
   PubMed Web of Science ®Google Scholar
• AlbitarSMeuldersQHammoudHSoutifCBouvierPPolliniJSubcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patientsNephrol Dial Transplant199510suppl 640438524493
   PubMed Web of Science ®Google Scholar
• McFarlanePAHillmerMPDacourisNA change from subcutaneous to intravenous erythropoietin increases the cost of anemia therapyNephron Clin Pract2007107c90c9617890876
   PubMedGoogle Scholar
• VercaigneLMCollinsDMPennerSBConversion from subcutaneous to intravenous erythropoietin in a hemodialysis populationJ Clin Pharmacol20054589590016027399
   PubMed Web of Science ®Google Scholar
• RaymondCBCollinsDMBernsteinKNSkwarchukDEVercaigneLMErythropoietin-alpha dosage requirements in a provincial hemodialy-sis population: effect of switching from subcutaneous to intravenous administrationNephron Clin Pract2006102c88c9216282700
   PubMedGoogle Scholar
• GallifordJWMalasanaRFarringtonKSwitching from subcutaneous to intravenous erythropoietin alpha in haemodialysis patients requires a major dose increaseNephrol Dial Transplant2005201956196215930017
   PubMed Web of Science ®Google Scholar
• RobinsonAMMcLeanKAGreavesMChannerKSSubcutaneous versus intravenous administration of heparin in the treatment of deep vein thrombosis; which do patients prefer? A randomized cross-over studyPostgrad Med J1993691151168506190
   PubMed Web of Science ®Google Scholar
• BarberNDHoffmeyerUKComparison of the cost-effectiveness of administering heparin subcutaneously or intravenously for the treatment of deep vein thrombosisAnn R Coll Surg Engl1993754304338285546
   PubMed Web of Science ®Google Scholar
• HonarmandASafaviMKarakyHPreincisional administration of intravenous or subcutaneous infiltration of low-dose ketamine suppresses postoperative pain after appendectomyJ Pain Res201251622328829
   PubMedGoogle Scholar
• JavidMJRahimiMKeshvariADissociative conscious sedation, an alternative to general anesthesia for laparoscopic peritoneal dialysis catheter implantation: a randomized trial comparing intravenous and subcutaneous ketaminePerit Dial Int20113130831421193552
   PubMed Web of Science ®Google Scholar
• RajGKumarRMcKinneyWPTime course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadioneArch Intern Med19991592721272410597763
   PubMed Web of Science ®Google Scholar
• NeeRDoppenschmidtDDonovanDJAndrewsTCIntravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulationAm J Cardiol199983286–288A6A7
   Google Scholar
• GauthierDSchambachSCrouzetJSirvainSFraisseTSubcutaneous and intravenous ceftriaxone administration in patients more than 75 years of ageMed Mal Infect20144427528024932703
   PubMed Web of Science ®Google Scholar
• HarbGLebelFBattikhaJThackaraJWSafety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteersCurr Med Res Opin20102627928819947907
   PubMed Web of Science ®Google Scholar
• DaoustRPaquetJLavigneGPietteÉChaunyJMImpact of age, sex and route of administration on adverse events after opioid treatment in the emergency department: a retrospective studyPain Res Manag201520232825664538
   PubMed Web of Science ®Google Scholar
• WalshDPerinMLMcIverBParenteral morphine prescribing patterns among inpatients with pain from advanced cancer: a prospective survey of intravenous and subcutaneous useAm J Hosp Palliat Care20062335335917060302
   PubMedGoogle Scholar
• CampbellRLBellolioMFKnutsonBDEpinephrine in anaphy-laxis: higher risk of cardiovascular complications and overdose after administration of intravenous bolus epinephrine compared with intramuscular epinephrineJ Allergy Clin Immunol Pract20153768025577622
   PubMed Web of Science ®Google Scholar
• FaustDRabenauHFAllwinnRCasparyWFZeuzemSCost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantationClin Transplant20031725425812780677
   PubMed Web of Science ®Google Scholar
• HanSHMartinPEdelsteinMConversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantationLiver Transpl2003918218712548512
   PubMed Web of Science ®Google Scholar
• FranciosiMCaccamoLDe SimonePTWINS I Study GroupDevelopment and validation of a questionnaire evaluating the impact of hepatitis B immune globulin prophylaxis on the quality of life of liver transplant recipientsLiver Transpl20121833233922139956
   PubMed Web of Science ®Google Scholar
• Oncaspar. [webpage on the Internet] Available from: http://www.rxlist.com/oncaspar-drug.htm. [updated 2014 May 2]Accessed March 29, 2015
   Google Scholar
• PidapartiMBostromBComparison of allergic reactions to pegas-paraginase given intravenously versus intramuscularlyPediatr Blood Cancer20125943643922021170
   PubMed Web of Science ®Google Scholar
• PetersenWCJrClarkDSennSLComparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemiaPediatr Hematol Oncol20143131131724498943
   PubMed Web of Science ®Google Scholar
• MilkovichGPiazzaCJConsiderations in comparing intravenous and intramuscular antibioticsChemotherapy199137suppl 21131879181
   PubMed Web of Science ®Google Scholar
• ChinAGillMAItoMKA cost comparison of intramuscular versus intravenous imipenemHosp Pharm19892490590910296145
   PubMedGoogle Scholar
• RadwanskiEBatraVCayenMPharmacokinetics of ise-pamicin following a single administration by intravenous infusion or intramuscular injectionsAntimicrob Agents Chemother199741179417969257763
   PubMed Web of Science ®Google Scholar
• AntonyKKLewisEWKennyMTPharmacokinetics and bioavailability of a new formulation of teicoplanin following intravenous and intramuscular administration to humansJ Pharm Sci1991806056071834827
   PubMed Web of Science ®Google Scholar
• GoonetillekeAKDevDAzizIHughesCSmithMJBasranGSA comparative analysis of pharmacokinetics of ceftriaxone in serum and pleural fluid in humans: a study of once daily administration by intramuscular and intravenous routesJ Antimicrob Chemother1996389699769023644
   PubMed Web of Science ®Google Scholar
• MomeniMEsfandbodMSaeediMFarniaMBasiraniRZebardastJComparison of the effect of intravenous ketamine and intramuscular ketamine for orthopedic procedures in children’s sedationInt J Crit Illn Inj Sci2014419119425337479
   PubMedGoogle Scholar
• RamaswamyPBablFEDeasyCSharwoodLNPediatric procedural sedation with ketamine: time to discharge after intramuscular versus intravenous administrationAcad Emerg Med20091610110719076105
   PubMed Web of Science ®Google Scholar
• RobackMGWathenJEMacKenzieTBajajLA randomized, controlled trial of i.v. versus i.m. ketamine for sedation of pediatric patients receiving emergency department orthopedic proceduresAnn Emerg Med20064860561217052563
   PubMed Web of Science ®Google Scholar
• DaleOThonerJNilsenTTveitaTBorchgrevinkPCKlepstadPSerum and cerebrospinal fluid morphine pharmacokinetics after single doses of intravenous and intramuscular morphine after hip replacement surgeryEur J Clin Pharmacol20076383784217619868
   PubMed Web of Science ®Google Scholar
• TveitaTThonerJKlepstadPDaleOJystadABorchgrevinkPCA controlled comparison between single doses of intravenous and intramuscular morphine with respect to analgesic effects and patient safetyActa Anaesthesiol Scand20085292092518702754
   PubMed Web of Science ®Google Scholar
• HendricksonMMyreLJohnsonDGMatlakMEBlackRESullivanJJPostoperative analgesia in children: a prospective study in intermittent intramuscular injection versus continuous intravenous infusion of morphineJ Pediatr Surg1990251851902303987
   PubMed Web of Science ®Google Scholar
• EllisRMSprivulisPCJelinekGAA double-blind, randomized trial of intravenous versus intramuscular antivenom for red-back spider envenomingEmerg Med Australas20051715215615796730
   PubMedGoogle Scholar
• IsbisterGKO’LearyMMillerMA comparison of serum antivenom concentrations after intravenous and intramuscular administration of redback (widow) spider antivenomBr J Clin Pharmacol20086513914318171334
   PubMed Web of Science ®Google Scholar
• SimonsFERobertsJRGuXSimonsKJEpinephrine absorption in children with a history of anaphylaxisJ Allergy Clin Immunol199810133379449498
   PubMed Web of Science ®Google Scholar
• HaymoreBRCarrWWFrankWTAnaphylaxis and epinephrine prescribing patterns in a military hospital: underutilization of the intramuscular routeAllergy Asthma Proc20052636136516450570
   PubMed Web of Science ®Google Scholar
• SimonsFEGuXSimonsKJEpinephrine absorption in adults: intramuscular versus subcutaneous injectionJ Allergy Clin Immunol200110887187311692118
   PubMed Web of Science ®Google Scholar
• REBIF. [webpage on the Internet] Available from: http://www.rxlist.com/rebif-drug/indications-dosage.htm. [updated 2014 May 12]Accessed March 29, 2015
   Google Scholar
• AVONEX®. [webpage on the Internet] Available from: http://www.rxlist.com/avonex-drug/indications-dosage.htm. [updated 2013 March 27]Accessed March 29, 2015
   Google Scholar
• GuoSBozkayaDWardATreating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implicationsPharmacoeconomics200927395319178123
   PubMed Web of Science ®Google Scholar
• CalabreseMBernardiVAtzoriMEffect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosisMult Scler20121841842421228025
   PubMed Web of Science ®Google Scholar
• HalpernRAgarwalSDembekCBortonLLopez-BresnahanMComparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysisPatient Prefer Adherence20115738421423591
   PubMed Web of Science ®Google Scholar
• BrooksPJSpruillWJParishRCBirchmoreDAPharmacokinet-ics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritisArthritis Rheum19903391942302272
   PubMed Web of Science ®Google Scholar
• JundtJWBrowneBAFioccoGPSteeleADMockDA comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosingJ Rheumatol19932011184518498308768
   PubMed Web of Science ®Google Scholar
• ArthurVJubbRHomerDA study of parenteral use of methotrexate in rheumatic conditionsJ Clin Nurs20021125626311903725
   PubMed Web of Science ®Google Scholar
• Müller-LadnerURockwitzKBrandt-JürgensJMC-MTX.10/RH Study GroupTolerability and patient/physician satisfaction with subcutaneously administered methotrexate provided in two formulations of different drug concentrations in patients with rheumatoid arthritisOpen Rheumatol J20104152220461222
   PubMedGoogle Scholar
• StellingJRChapmanETFrankfurterDHarrisDHOskowitzSPReindollarRHSubcutaneous versus intramuscular administration of human chorionic gonadotropin during an in vitro fertilization cycleFertil Steril20037988188512749424
   PubMed Web of Science ®Google Scholar
• ShahDKMissmerSACorreiaKFGinsburgESPharmacokinetics of human chorionic gonadotropin injection in obese and normal-weight womenJ Clin Endocrinol Metab2014991314132124476082
   PubMed Web of Science ®Google Scholar
• SinghamJGreanyaEDLauKErbSRPartoviNYoshidaEMEfficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxis against hepatitis B recurrenceAnn Hepatol2010916617120526010
   PubMed Web of Science ®Google Scholar
• KleinCGCicinnatiVSchmidtHCompliance and tolerability of subcutaneous hepatitis B immunoglobulin self-administration in liver transplant patients: a prospective, observational, multicenter studyAnn Transplant20131867768424335787
   PubMed Web of Science ®Google Scholar
• ThürmannPASzymanskiJHaffnerSTenterUGriegerFSonnenburgCPharmacokinetics and safety of a novel anti-HBs-enriched immunoglobulin in healthy volunteers after subcutaneous and intramuscular administrationEur J Clin Pharmacol20066251151216676173
   PubMed Web of Science ®Google Scholar
• HahnerSBurger-StrittSAllolioBSubcutaneous hydrocortisone administration for emergency use in adrenal insufficiencyEur J Endocrinol201316914715423672956
   PubMed Web of Science ®Google Scholar
• CooperIMMorphine for postoperative analgesia. A comparison of intramuscular and subcutaneous routes of administrationAnaesth Intensive Care1996245745788909669
   PubMed Web of Science ®Google Scholar
• ThomasJRYocumRCHallerMFFlamentJThe INFUSE-morphine IIB study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneous morphine in healthy volunteersJ Pain Symptom Manage20093867368219819667
   PubMed Web of Science ®Google Scholar
• ThomasJRWallaceMSYocumRCVaughnDEHallerMFFlamentJThe INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illnessJ Pain Symptom Manage20093866367219819665
   PubMed Web of Science ®Google Scholar
• YangHHengXLiangCComparison of continuous subcutaneous insulin infusion and multiple daily insulin injections in Chi-nese patients with type 2 diabetes mellitusJ Int Med Res2014421002101024965335
   PubMed Web of Science ®Google Scholar
• Calcium gluconate injection. [webpage on the Internet] Available from: http://www.rxlist.com/calcium-gluconate-drug.htm. [updated 2009 April 2]Accessed May 1, 2015
   Google Scholar
• Promethazine hydrochloride injection. [webpage on the Internet] Available from: http://www.rxlist.com/promethazine-hcl-injection-drug/indications-dosage.htm. [updated 2007 June 21]Accessed May 1, 2015
   Google Scholar
• Norepinephrine bitartrate injection. [webpage on the Internet] Available from: http://www.rxlist.com/levophed-drug/warnings-precautions.htm. [updated 2012 December 2]Accessed May 1, 2015
   Google Scholar
• WeissLGClyneNDivino FihlhoJFrisenette-FichCKurkusJSvenssonBThe efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multicentre trial. Swedish Study GroupNephrol Dial Transplant2000152014201911096148
   PubMed Web of Science ®Google Scholar
• BringhenSLaroccaARossiDEfficacy and safety of once-weekly bortezomib in multiple myeloma patientsBlood20101164745475320807892
   PubMed Web of Science ®Google Scholar